Table 6.
Regression modeling for time to relapse and discontinuation from PP3M and PPLAI.
| Model | Time to relapse (PP3M) | Time to discontinuation (PP3M) | Time to relapse (PPLAI) | Time to discontinuation (PPLAI) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covariates | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value |
| Age | 0.97 | (0.93, 1.00) | 0.056 | 0.97 | (0.95, 0.99) | 0.017 | 0.96 | (0.93, 0.99) | 0.045 | 0.95 | (0.93, 0.98) | <0.001 |
| Inpatient | 0.81 | (0.31, 2.10) | 0.662 | 1.54 | (0.89, 2.65) | 0.121 | 0.90 | (0.36,2.23) | 0.816 | 1.75 | (0.88, 3.47) | 0.109 |
| Male gender | 0.84 | (0.31, 2.31) | 0.741 | 0.52 | (0.30, 0.88) | 0.016 | 0.79 | (0.32,1.92) | 0.606 | 0.60 | (0.31, 1.17) | 0.132 |
| Polypharmacy | 7.91 | (2.73, 22.9) | <0.001 | 1.05 | (0.53, 2.04) | 0.897 | 6.45 | (2.49, 16.5) | <0.001 | 0.92 | (0.42, 1.99) | 0.831 |
| Ethnicity | 1.37 | (0.48, 4.21) | 0.586 | 1.18 | (0.65, 2.15) | 0.581 | 1.19 | (0.41,3.48) | 0.754 | 0.79 | (0.35,1.79) | 0.572 |
| Dose | 0.86 | (0.48, 1.51) | 0.594 | 0.97 | (0.73, 1.31) | 0.857 | 0.90 | (0.52,1.54) | 0.692 | 1.13 | (0.78, 1.63) | 0.524 |
| Prior clozapine | 6.11 | (1.82, 20.5) | 0.003 | 1.87 | (1.05, 3.30) | 0.032 | 4.52 | (1.51, 13.5) | 0.007 | 1.15 | (0.54, 2.41) | 0.721 |
| F20 | 0.17 | (0.06, 0.50) | 0.001 | 0.62 | (0.34, 1.13) | 0.119 | 0.21 | (0.08, 0.58) | 0.002 | 0.429 | (0.21, 0.87) | 0.018 |
Abbreviations: CI, confidence intervals; HR, hazard ratio; PPLAI, paliperidone long-acting injection; PP3M, Paliperidone 3-monthly; SD, standard deviation.